Trial · NCT02517398
Adverse events12,581
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 12,581Pages stop at row 10,000
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Dose-escalation: M7824 0.3 - 10 mg/kg | 1 | 3 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-escalation: M7824 1 mg/kg | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-escalation: M7824 1 - 1200 mg | 1 | 4 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-escalation: M7824 10 mg/kg | 2 | 6 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-escalation: M7824 20 mg/kg | 5 | 10 | 13 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-escalation: M7824 2400 mg/Infusion | 2 | 3 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-escalation: M7824 3 mg/kg | 1 | 3 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-escalation: M7824 30 mg/kg | 4 | 7 | 12 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: Cervical Cancer | 7 | 15 | 18 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: Colorectal Carcinoma | 10 | 32 | 32 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: Esophageal Adenocarcinoma | 11 | 30 | 28 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: Glioblastoma | 3 | 35 | 9 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: HCC-2L | 24 | 68 | 58 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-escalation: HCC-3 mg/kg | 1 | 6 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: HCC Ascending Dose 1200mg | 9 | 38 | 16 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: Melanoma PD-L1 Fail | 6 | 32 | 12 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: NSCLC-2L 1200 mg | 6 | 40 | 10 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: NSCLC-2L 500 mg | 9 | 40 | 19 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: NSCLC Biomarker | 13 | 41 | 23 |
| other | Anaemia | Blood and lymphatic system disorders | Dose-expansion: NSCLC PD-L1 Fail | 25 | 83 | 51 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02517398/events